PrEP

US: Potential new PrEP drug exposes gaps in data for women

The possibility of new PrEP drug raises questions about how to fix gaps in data on women. Medicare will cover CAR-T cell therapy with significant moves to broaden administration and eligible patients. Sarepta denies a serious patient response to its Duchenne’s therapy, but its stock plunges.